these are mainline high revenue drugs that are the
Post# of 72440
I don't see one indication that shouldn't bring in whatever BP gets the rights to it a lifetime of revenues under $12B to be extremely conservative.
As such, IPIX better be raking in multi billions.
Won't be long now til we find out whether that view is right or wrong.